Review article: COX-2, prostanoids and colon cancer

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 16, Issue 2, 2002, Pages 102-106

  Ota, S ^a   Bamba, H ^a   Kato, A ^b   Kawamoto, C ^b   Yoshida, Y ^b   Fujiwara, K ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GROWTH FACTOR; MEMBRANE RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN; PROSTANOID; CELL RECEPTOR; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

CANCER INHIBITION; CARCINOGENESIS; COLON ADENOMA; COLON CANCER; HUMAN; LEYDIG CELL; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; TUMOR CELL; ANIMAL; COLON TUMOR; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 1642468211     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Smalley W, Dubois RN. Colorectal cancer and nonsteroidal anti- inflammatory drugs. Adv Pharmacol 1997; 39: 1-20.
2. Shift SJ, Basil R. Nonsteroidal anti-inflammatory drugs and colorectal cancer: Evolving concepts of their chemopreventive actions. Gastroenterology 1997; 113: 1992-8.
3. Giardielo FM, Hamilton SR, Krush A, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. New Engl J Med 1993; 328: 1313-6.
4. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-8.
5. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785-9.
6. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and 2 protein in human colon cancer. Cancer Res 1995; 55: 2556-9.
7. Dubois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996; 110: 1252-62.
8. Williams CS, Luongo C, Radhika AA, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996; 111: 1134-40.
9. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409-12.
10. Yoshimi N, Kawabata K, Hara A, Matsunaga K, Yamada Y, Mori H. Inhibitory effect of NS-398, a selective cyclooxygenase inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn J Cancer Res 1997; 88: 1044-51.
11. Yoshimi N, Shimizu M, Matsunaga K, Yamada Y, Fujii K, Hara A, et al. Chemopreventive effect of N-(2-cyclohexy-4-nitrophenyl) methanesulfonamide (NS-398), a selective cyclooxygenase inhibitor, in rat colon carcinogenesis induced by azoxymethane. Jpn J Cancer Res 1999; 90: 406-12.
12. Fukutake M, Nakatsugi S, Isoi T, Takahashi M, Ohta T, Mamiya P, et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced coloncarcinogenesis in mice. Carcinogenesis 1998; 19: 1939-12.
13. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase- 2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000; 60: 5040-4.
14. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in APCΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996: 87: 803-9.
15. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
16. Waddel WR, Laughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83-7.
17. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM. Effect of long-term sulindac therapy on colonic polyposis. Ann Int Med 1991; 115: 952.
18. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized control trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80: 1618-9.
19. Matsuhashi N, Nakajima A, Fukushima Y, Yazaki Y, Oka T. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 1977; 40: 344-9.
20. Hull Man Booth JK, Tisbury A, Scott N, Bonifer C, Markham AF et al. Cyclooxygenase-2 is up-regulated and localized to macrophages in the intestine of Min mice. Br J Cancer 1999; 79: 1399-405.
21. Bamba H, Ota S, Kato A, Adachi A, Itoyama S, Matsuzaki F. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer 1999; 83: 470-5.
22. Chapple KS, Cartwright EJ, Hawcroft G, et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000; 156: 545-53.
23. Hull M, Chapple K, Coletta L, Poulsom R. COX-2 in murine intestinal tumors. Gastroenterology 2000; 119: 600-2.
24. Shattuck-Brandt RL, Varilek GW, Radhika A, et al. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10 (-/-) mice. Gastroenterology 2000; 118: 337-45.
25. Hanif R, Pittas A, Feng Y, Koutsos MI, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52: 237-15.
26. 2 in human colon cancer cells. Cancer Res 1998; 58: 362-6.
27. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-89.
28. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4: 1046-52.
29. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998; 4: 1053-7.
30. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 1998; 4: 1058-61.
31. DuBois RN, Gupta R, Brockman J, et al. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 1998; 19: 49-53.
32. Brockman JA, Gupta RA, Dubois RN. Activation of PPAR-gamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998; 115: 1049-55.
33. Kitamura S, Miyazaki Y, Shinomura Y, et al. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999; 90: 75-80.
34. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335, 36-45.
35. Lim H, Gupta RA, Ma WG, et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ. Genes Dev 1999; 13: 1561-74.
36. Ota S, Bamba H, Kato A. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Acta Pharmacololgica Sinica 2000; 21(5): 391-5.
37. Matsumoto K, Okazaki H, Nakamura T. Novel function of prostaglandins as inducers of gene expression of HGF and putative mediators of tissue regeneration. J Biochem (Tokyo) 1995; 117: 458-64.
38. Takahashi M, Ota S, Hata Y, et al. Hepatocyte growth factor as a key to modulate anti-ulcer action of prostaglandins in stomach. J Clin Invest 1996; 98: 2604-11.
39. Bamba H, Ota S, Kato A, Matsuzaki F. Nonsteroidal anti-inflammatory drugs may delay the repair of gastric mucosa by suppressing prostaglandin-mediated increase of hepatocyte growth factor production. Biochem Biophys Res Commun 1998; 245: 567-71.
40. Ota S, Tanaka Y, Bamba H, Kato A, Matsuzaki F. Nonsteroidal anti-inflammatory drugs may prevent colon cancer through suppression of hepatocyte growth factor expression. Eur J Pharmacol 1999; 367: 131-8.
41. Bamba H, Ota S, Kato A, Kawamoto C, Fujiwara K. Prostaglandins Up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells. Biochem Biophys Res Commun 2000; 273: 485-91.
42. Yamakawa K, Hosoi M, Koyama H. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 2000; 271: 571-4.
43. 1 on vascular endothelial growth factor production by human macrophages and colon cancer cells. J Exp Clin Cancer Res 2000; 19: 219-23.
44. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 1999; 3: 799-804.